Eli Lilly Reports Pivotal Trial Results for Next-gen Obesity Drug Retatrutide
Eli Lilly (LLY) announced that its next-generation obesity drug, retatrutide, achieved up to 28% weight loss over 80 weeks in a pivotal Phase 3 trial called TRIUMPH-1. The therapy targets GIP, GLP-1, and glucagon triple hormone receptors.
Tickers: $LLY
Topics: pharmaceuticals Phase-3-trials weight_loss